306 related articles for article (PubMed ID: 28432226)
1. Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Generali D; Montemurro F; Bordonaro R; Mafodda A; Romito S; Michelotti A; Piovano P; Ionta MT; Bighin C; Sartori D; Frassoldati A; Cazzaniga ME; Riccardi F; Testore F; Vici P; Barone CA; Schirone A; Piacentini F; Nolè F; Molino A; Latini L; Simoncini EL; Roila F; Cognetti F; Nuzzo F; Foglietta J; Minisini AM; Goffredo F; Portera G; Ascione G; Mariani G
Oncologist; 2017 Jun; 22(6):648-654. PubMed ID: 28432226
[TBL] [Abstract][Full Text] [Related]
2. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Jerusalem G; Mariani G; Ciruelos EM; Martin M; Tjan-Heijnen VC; Neven P; Gavila JG; Michelotti A; Montemurro F; Generali D; Simoncini E; Lang I; Mardiak J; Naume B; Camozzi M; Lorizzo K; Bianchetti S; Conte P
Ann Oncol; 2016 Sep; 27(9):1719-25. PubMed ID: 27358383
[TBL] [Abstract][Full Text] [Related]
3. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Ciruelos E; Vidal M; Martínez de Dueñas E; Martínez-Jáñez N; Fernández Y; García-Sáenz JA; Murillo L; Carabantes F; Beliera A; Fonseca R; Gavilá J
Clin Transl Oncol; 2018 Jun; 20(6):753-760. PubMed ID: 29116433
[TBL] [Abstract][Full Text] [Related]
4. Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.
Moscetti L; Vici P; Gamucci T; Natoli C; Cortesi E; Marchetti P; Santini D; Giuliani R; Sperduti I; Mauri M; Pizzuti L; Mancini ML; Fabbri MA; Magri V; Iezzi L; Sini V; D'Onofrio L; Mentuccia L; Vaccaro A; Ramponi S; Roma CL; Ruggeri EM
Breast; 2016 Oct; 29():96-101. PubMed ID: 27476084
[TBL] [Abstract][Full Text] [Related]
5. Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
Ciruelos E; Jerusalem G; Martin M; Tjan-Heijnen VCG; Neven P; Gavila J; Montemurro F; Generali D; Lang I; Martínez-Serrano MJ; Perelló MF; Conte P
Clin Transl Oncol; 2020 Oct; 22(10):1857-1866. PubMed ID: 32170637
[TBL] [Abstract][Full Text] [Related]
6. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
Rugo HS; Seneviratne L; Beck JT; Glaspy JA; Peguero JA; Pluard TJ; Dhillon N; Hwang LC; Nangia C; Mayer IA; Meiller TF; Chambers MS; Sweetman RW; Sabo JR; Litton JK
Lancet Oncol; 2017 May; 18(5):654-662. PubMed ID: 28314691
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and Safety of Everolimus plus Exemetane in Postmenopausal Endocrine-Responsive Metastatic Breast Cancer Patients].
Maeda N; Yamamoto S; Sato Y; Sakamoto K; Suzuki N; Takeda S; Nagashima Y; Kubo H; Nagano H
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1260-1262. PubMed ID: 29394600
[TBL] [Abstract][Full Text] [Related]
9. [Everolimus plus Exemestane in Postmenopausal Metastatic Breast Cancer Patients].
Yamamoto D; Tsubota Y; Sueoka N; Yamamoto C; Kon M
Gan To Kagaku Ryoho; 2015 Oct; 42(10):1319-21. PubMed ID: 26489585
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
Cazzaniga ME; Airoldi M; Arcangeli V; Artale S; Atzori F; Ballerio A; Bianchi GV; Blasi L; Campidoglio S; Ciccarese M; Cursano MC; Piezzo M; Fabi A; Ferrari L; Ferzi A; Ficorella C; Frassoldati A; Fumagalli A; Garrone O; Gebbia V; Generali D; La Verde N; Maur M; Michelotti A; Moretti G; Musolino A; Palumbo R; Pistelli M; Porpiglia M; Sartori D; Scavelli C; Schirone A; Turletti A; Valerio MR; Vici P; Zambelli A; Clivio L; Torri V; ;
Breast; 2017 Oct; 35():115-121. PubMed ID: 28711793
[TBL] [Abstract][Full Text] [Related]
11. Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Ciccarese M; Fabi A; Moscetti L; Cazzaniga ME; Petrucelli L; Forcignanò R; Lupo LI; De Matteis E; Chiuri VE; Cairo G; Febbraro A; Giordano G; Giampaglia M; Bilancia D; La Verde N; Maiello E; Morritti M; Giotta F; Lorusso V; Latorre A; Scavelli C; Romito S; Cusmai A; Palmiotti G; Surico G
Breast Cancer Res Treat; 2017 Jun; 163(3):587-594. PubMed ID: 28353061
[TBL] [Abstract][Full Text] [Related]
12. [An Elderly Patient with Metastatic Breast Cancer Who Developed Severe Adverse Events such as Stomatitis and Interstitial Pneumonia after Everolimus plus Exemestane Treatment].
Sakiyama K; Yoshida T; Goto Y; Kimura M
Gan To Kagaku Ryoho; 2016 Jun; 43(6):753-5. PubMed ID: 27306814
[TBL] [Abstract][Full Text] [Related]
13. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Jerusalem G; de Boer RH; Hurvitz S; Yardley DA; Kovalenko E; Ejlertsen B; Blau S; Özgüroglu M; Landherr L; Ewertz M; Taran T; Fan J; Noel-Baron F; Louveau AL; Burris H
JAMA Oncol; 2018 Oct; 4(10):1367-1374. PubMed ID: 29862411
[TBL] [Abstract][Full Text] [Related]
14. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
Campone M; Yang H; Faust E; Kageleiry A; Signorovitch JE; Zhang J; Gao H
J Med Econ; 2014 Dec; 17(12):837-45. PubMed ID: 25164472
[TBL] [Abstract][Full Text] [Related]
15. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Schmid P; Sablin MP; Bergh J; Im SA; Lu YS; Martínez N; Neven P; Lee KS; Morales S; Pérez-Fidalgo JA; Adamson D; Gonçalves A; Prat A; Jerusalem G; Schlieker L; Espadero RM; Bogenrieder T; Huang DC; Crown J; Cortés J
Breast Cancer Res; 2021 Jan; 23(1):8. PubMed ID: 33451345
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Pritchard KI; Burris HA; Ito Y; Rugo HS; Dakhil S; Hortobagyi GN; Campone M; Csöszi T; Baselga J; Puttawibul P; Piccart M; Heng D; Noguchi S; Srimuninnimit V; Bourgeois H; Gonzalez Martin A; Osborne K; Panneerselvam A; Taran T; Sahmoud T; Gnant M
Clin Breast Cancer; 2013 Dec; 13(6):421-432.e8. PubMed ID: 24267730
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
Lüftner D; Schuetz F; Schneeweiss A; Hartkopf A; Bloch W; Decker T; Uleer C; Stötzer O; Foerster F; Schmidt M; Mundhenke C; Tesch H; Jackisch C; Fischer T; Kreuzeder J; Guderian G; Fasching PA
Int J Cancer; 2024 Jul; 155(1):128-138. PubMed ID: 38447007
[TBL] [Abstract][Full Text] [Related]
19. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Baselga J; Campone M; Piccart M; Burris HA; Rugo HS; Sahmoud T; Noguchi S; Gnant M; Pritchard KI; Lebrun F; Beck JT; Ito Y; Yardley D; Deleu I; Perez A; Bachelot T; Vittori L; Xu Z; Mukhopadhyay P; Lebwohl D; Hortobagyi GN
N Engl J Med; 2012 Feb; 366(6):520-9. PubMed ID: 22149876
[TBL] [Abstract][Full Text] [Related]
20. Everolimus Plus Letrozole for Treatment of Patients With HR
Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
